Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Clinical Pearls:
Roundtable Roundup: Early-Line Use of CAR T-cell Therapy in Multiple Myeloma
October 22nd 2024In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with relapsed/refractory multiple myeloma and how often participants use chimeric antigen receptor (CAR) T-cell therapy.
Read More